English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/151417
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids

AutorCaretti, Anna; Vasso, Michele; Bonezzi, Fabiola Tecla; Gallina, Andrea; Trinchera, Marco; Rossi, Alice; Adami, Raffella; Casas, Josefina; Falleni, Monica; Tosi, Delfina; Bragonzi, Alessandra; Ghidoni, Riccardo; Gelfi, Cecilia; Signorelli, Paola
Palabras claveCeramide
Cystic fibrosis
Inflammation
Mass Spectrometry
Myriocin
Fecha de publicación24-abr-2017
EditorSpringer
CitaciónNaunyn Schmiedeberg's Archives of Pharmacology 390: 1–16 (2017)
ResumenOur aim was to use quantitative and qualitative analyses to gain further insight into the role of ceramide in cystic fibrosis (CF). Sphingolipid ceramide is a known inflammatory mediator, and its accumulation in inflamed lung has been reported in different types of emphysema, chronic obstructive pulmonary disease and CF. CF is caused by a mutation of the chloride channel and associated with hyperinflammation of the respiratory airways and high susceptibility to ongoing infections. We have previously demonstrated that de novo ceramide synthesis is enhanced in lung inflammation and sustains Pseudomonas aeruginosa pulmonary infection in a CF murine model. We used liquid chromatography and matrix-assisted laser desorption/ionization (MALDI) imaging coupled with mass spectrometry, confocal laser scan microscopy and histology analyses to reveal otherwise undecipherable information. We demonstrated that (i) upregulated ceramide synthesis in the alveoli is strictly related to alveolar infection and inflammation, (ii) alveolar ceramide (C16) can be specifically targeted by nanocarrier delivery of the ceramide synthesis inhibitor myriocin (Myr) and (iii) Myr is able to downmodulate pro-inflammatory lyso-PC, favouring an increase in anti-inflammatory PCs. We concluded that Myr modulates alveolar lipids milieu, reducing hyperinflammation and favouring anti-microbial effective response in CF mouse model. © 2017 Springer-Verlag Berlin Heidelberg
Versión del editor10.1007/s00210-017-1373-4
URIhttp://hdl.handle.net/10261/151417
DOI10.1007/s00210-017-1373-4
Aparece en las colecciones: (IQAC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
17 Naunyn Sch Arch Pharmacol maldi preprint-1.pdf2,28 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.